Overall, the pharmacological profile of givinostat makes it an efficient, safe, and well-tolerated compound, as demonstrated by both pre-clinical and clinical observations, representing an ideal drug for the therapy of pediatric CRLF2r BCP-ALL patients [27]. The gene discussed is OPN1SW; the disease is acute lymphoblastic leukemia.